Another pharmaceutical chief executive is riding off into the sunset, the latest departure in an industry struggling to invent new medicines amid unprecedented pricing pressure.
Novo Nordisk A/S’s Lars Rebien Soerensen, chosen by Harvard Business Review as the world’s best-performing CEO last year, is retiring from the world’s biggest maker of insulin, the company said Thursday. He joins Gilead Sciences Inc.’s John Martin and Eli Lilly & Co.’s John Lechleiter in yielding the reins to a company veteran.
